SUGAR CHAIN-ADDED AILIM EXTRACELLULAR DOMAIN AND METHOD FOR PRODUCING SAME
Disclosed is a synthetic AILIM extracellular domain which has high ligand-binding ability and a quality sufficient for a pharmaceutical product. Also disclosed is a method for synthesizing the synthetic AILIM extracellular domain. Specifically disclosed is a sugar chaim-added AILIM extracellular domain wherein a sugar chain is bound at a position corresponding to the 69-position of the amino acid sequence of human AILIM extracellular domain, said amino acid sequence being depicted in SEQ ID NO: 7, and no sugar chain is added at positions corresponding to the 3-position and the 90-position of the amino acid sequence.
1 . An oligosaccharide chain-added extracellular domain of AILIM, comprising an extracellular domain of AILIM which comprises an oligosaccharide chain bound to a position corresponding to position 69 in the amino acid sequence of the extracellular domain of human AILIM represented by SEQ ID NO: 7, and no oligosaccharide chain added to a position corresponding to position 3 or 90 therein.
2 . An oligosaccharide chain-added extracellular domain of AILIM, comprising an extracellular domain of AILIM which comprises an oligosaccharide chain bound only to a position corresponding to position 69 in the amino acid sequence of the extracellular domain of human AILIM represented by SEQ ID NO: 7.
3 . The oligosaccharide chain-added extracellular domain of AILIM according to claim 1 , wherein the oligosaccharide chain is an oligosaccharide chain represented by
wherein R 1 and R 2 , which are the same or different, each represent
and Ac represents an acetyl group.
4 . An oligosaccharide chain-added extracellular domain of AILIM, comprising an extracellular domain of AILIM which consists of the amino acid sequence represented by SEQ ID NO: 7, the extracellular domain comprising the following asialo-nonasaccharide chain bound only to Asn 69 of SEQ ID NO: 7:
5 . The oligosaccharide chain-added extracellular domain according to claim 1 , wherein the oligosaccharide chain is substantially homogeneous.
6 . A method for producing an oligosaccharide chain-added extracellular domain of AILIM, comprising the steps of:
dividing the oligosaccharide chain-added extracellular domain of AILIM into the fragment A corresponding to a region of positions 1 to 42 in the amino acid sequence of the extracellular domain of human AILIM represented by SEQ ID NO: 7, the fragment B corresponding to a region of positions 43 to 62, the fragment C corresponding to a region of positions 63 to 88 and comprising an oligosaccharide chain-added position corresponding to position 69, and the fragment D corresponding to a region of position 89 to the C-terminus; and
preparing the fragments A to D, comprising: introducing a protective group to the thiol group of Cys corresponding to position 22 in the fragment A; adding an oligosaccharide chain to Asn corresponding to position 69 in the fragment C; and introducing a protective group to the respective thiol groups of Cys 116 and Cys 117 in the fragment D;
thioesterifying the respective C-termini of the fragments A to C;
linking the fragments A and B by a KCL method;
linking the fragments C and D by an NCL method; and
linking the fragments A and B thus linked and the fragments C and D thus linked by the NCL method.
7 . The method according to claim 6 , wherein the preparation of the fragment A is performed by a solid-phase synthesis method, wherein in the solid-phase synthesis method, Cys having a protective group introduced to the thiol group is used as the Cys corresponding to position 22 in the amino acid sequence of the extracellular domain of human AILIM represented by SEQ ID NO: 7.
8 . The method according to claim 6 , wherein the preparation of the fragment C is performed by a solid-phase synthesis method, wherein in the solid-phase synthesis method, oligosaccharide chain-added asparagine is used as the Asn corresponding to position 69 in the amino acid sequence of the extracellular domain of human AILIM represented by SEQ ID NO: 7.
9 . The method according to claim 6 , wherein the preparation of the fragment D is performed by a solid-phase synthesis method, wherein in the solid-phase synthesis method, Cys having a protective group introduced to the thiol group is used as each of the Cys 116 and the Cys 117 in the amino acid sequence of the extracellular domain of human AILIM represented by SEQ ID NO: 7.
10 . The method according to claim 7 , wherein the solid-phase synthesis method is an Fmoc solid-phase synthesis method.
11 . The method according to claim 7 , wherein the Fmoc solid-phase synthesis method comprises microwave irradiation in amino acid condensation reaction and/or Fmoc group elimination reaction.
12 . The method according to claim 6 , wherein the oligosaccharide chain is an oligosaccharide chain represented by
wherein R 1 and R 2 , which are the same or different, each represent
and Ac represents an acetyl group.
13 . The method according to claim 12 , wherein the oligosaccharide chain is the following asialo-nonasaccharide chain:
14 . An oligosaccharide chain-added extracellular domain of AILIM produced by a method according to claim 6 , wherein the oligosaccharide chain is substantially homogeneous.
15 . A pharmaceutical composition comprising an oligosaccharide chain-added extracellular domain of AILIM according to claim 1 as an active ingredient.
16 . The pharmaceutical composition according to claim 15 , wherein the pharmaceutical composition is intended for the treatment or prevention of an AILIM-related disease.
17 . The pharmaceutical composition according to claim 15 , wherein the pharmaceutical composition is an immunosuppressive agent.
18 . An immunosuppression method comprising administering an oligosaccharide chain-added extracellular domain of AILIM according to claim 1 or a pharmaceutical composition thereof.